Biocartis Group NV (EUR)
BCART
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range5.91 | 6.04
52-Wk Range5.40 | 12.52
Last Close6.04
Mkt Cap (m)340.55
Dividend yield-
ISINBE0974281132
Volume126,460
Exchange VenueBRU

Company Profile

Biocartis Group NV along with its subsidiaries develops proprietary molecular diagnostics platform offering molecular information from any biological sample, enabling fast and effective diagnostics treatment selection and treatment progress monitoring.

Key Information
Price/Earning-
Price/Book2.75
Price/Sales9.90
P/CF-
Rev Growth (3 year avg)27.77
EPS Growth (3 year avg)-
Operating Margin % -156.63
Net Margin %-173.14
Return on Equity-43.86
Debt/Equity0.40

Legal Documents

Prospectus
en 14/04/2015
Annual Report
en 31/12/2018

Financials

Income Statement
EUR201320142015201620172018
Revenue (m)8813122128
Operating Income (m)-26-29-40-50-44-44
Net Income (m)-36-9-40-50-42-48
Basic EPS-1.40-0.36-1.07-1.21-0.93-0.94
Avg. Diluted Shares Outstanding (m)262637414551
Balance Sheet
EUR201320142015201620172018
Current Assets (m)393311810013391
Non Current Assets (m)222030414849
Total Assets (m)6053148141181139
Current Liabilities (m)121828151620
Total Liabilities (m)------
Total Equity (m)32201159713287
Cash Flows
EUR201320142015201620172018
Operating Cash Flows (m)-41-36-23-53-41-42
Capital Expenditure (m)-4-3-10-11-4-6
Figures are quoted in EUR unless stated otherwise
-0.12 (-1.99%)
5.92
Last Price